{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T13:40:18Z","timestamp":1770558018373,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.acuroe.2025.501798","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T12:04:43Z","timestamp":1751889883000},"page":"501798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Acute toxicity of SBRT in localized prostate cancer: A Spanish multicenter study"],"prefix":"10.1016","volume":"49","author":[{"given":"S.E.","family":"Romero Zoghbi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"L\u00f3pez Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Sanz-Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Fern\u00e1ndez Ibiza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.J.","family":"Thuissard-Vasallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Andreu-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Laria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Andreescu Yag\u00fce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Krumina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ocanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.A.","family":"Glar\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Garc\u00eda Cuesta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Begara de la Fuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"L\u00f3pez Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Aakki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Gonz\u00e1lez Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ristori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.B.","family":"Bezares Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Larrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Garc\u00eda Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cou\u00f1ago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2025.501798_bib0005","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1158\/1055-9965.EPI-10-0437","article-title":"Global patterns of cancer incidence and mortality rates and trends","volume":"19","author":"Jemal","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"10.1016\/j.acuroe.2025.501798_bib0010","series-title":"Estimaciones de la incidencia del c\u00e1ncer en Espa\u00f1a, 2025","year":"2025"},{"key":"10.1016\/j.acuroe.2025.501798_bib0015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2025.501798_bib0020","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.acuroe.2025.501798_bib0025","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.acuroe.2025.501798_bib0030","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.radonc.2020.09.053","article-title":"Dose-response with stereotactic body radiotherapy for prostate cancer: a multi-institutional analysis of prostate-specific antigen kinetics and biochemical control","volume":"154","author":"Levin-Epstein","year":"2021","journal-title":"Radiother Oncol."},{"issue":"110568","key":"10.1016\/j.acuroe.2025.501798_bib0035","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.acuroe.2025.501798_bib0040","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ijrobp.2023.05.004","article-title":"Toxicity and patient-reported quality-of-life outcomes after prostate stereotactic body radiation therapy with focal boost to magnetic resonance imaging-identified prostate cancer lesions: results of a phase 2 trial","volume":"117","author":"Morris","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.acuroe.2025.501798_bib0045","series-title":"Plymouth Meeting","article-title":"NCCN Clinical Practice Guidelines in Oncology: prostate cancer. Version 1.2024","year":"2024"},{"key":"10.1016\/j.acuroe.2025.501798_bib0050","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1007\/s00432-021-03785-2","article-title":"Five-year outcomes of stereotactic body radiation therapy (SBRT) for prostate cancer: the largest experience in China","volume":"147","author":"Zhao","year":"2021","journal-title":"J Cancer Res Clin Oncol."},{"key":"10.1016\/j.acuroe.2025.501798_bib0055","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints","volume":"102","author":"Meier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.acuroe.2025.501798_bib0060","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fonc.2016.00184","article-title":"The comparison of stereotactic body radiation therapy and intensity-modulated radiation therapy for prostate cancer by NCCN Risk Groups","volume":"6","author":"Ricco","year":"2016","journal-title":"Front Oncol."},{"key":"10.1016\/j.acuroe.2025.501798_bib0065","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijrobp.2020.09.054","article-title":"Prostate stereotactic body radiation therapy: an overview of toxicity and dose response","volume":"110","author":"Wang","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.acuroe.2025.501798_bib0070","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1748-717X-9-163","article-title":"Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer","volume":"9","author":"Arscott","year":"2014","journal-title":"Radiat Oncol."},{"key":"10.1016\/j.acuroe.2025.501798_bib0075","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.3389\/fonc.2020.01060","article-title":"Stereotactic Body Radiation Therapy (SBRT) for prostate cancer in men with a high baseline International Prostate Symptom Score (IPSS \u2265 15)","volume":"10","author":"Aghdam","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.acuroe.2025.501798_bib0080","article-title":"Urinary outcomes for men with high baseline international prostate symptom scores treated with prostate SBRT","volume":"6","author":"Gorovets","year":"2020","journal-title":"Adv Radiat Oncol."},{"key":"10.1016\/j.acuroe.2025.501798_bib0085","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13014-014-0241-3","article-title":"Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (\u226550 cm(3))","volume":"9","author":"Janowski","year":"2014","journal-title":"Radiat Oncol."},{"key":"10.1016\/j.acuroe.2025.501798_bib0090","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"PACE Trial Investigators. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.acuroe.2025.501798_bib0095","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.acuroe.2025.501798_bib0100","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.acuroe.2025.501798_bib0105","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"CHHiP Investigators. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.acuroe.2025.501798_bib0110","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuroe.2025.501798_bib0115","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuroe.2025.501798_bib0120","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.ijrobp.2022.12.022","article-title":"Five-year patient-reported outcomes in NRG oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer","volume":"116","author":"Lukka","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.acuroe.2025.501798_bib0125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE Randomized Clinical Trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.acuroe.2025.501798_bib0130","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"PACE Trial Investigators. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.acuroe.2025.501798_bib0135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.722852","article-title":"Bleeding risk following stereotactic body radiation therapy for localized prostate cancer in men on baseline anticoagulant or antiplatelet therapy","volume":"11","author":"Pepin","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.acuroe.2025.501798_bib0140","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13014-015-0488-3","article-title":"Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer","volume":"10","author":"Rana","year":"2015","journal-title":"Radiat Oncol."}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578625001313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578625001313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:16:40Z","timestamp":1759342600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578625001313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2173578625001313"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2025.501798","relation":{},"ISSN":["2173-5786"],"issn-type":[{"value":"2173-5786","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute toxicity of SBRT in localized prostate cancer: A Spanish multicenter study","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2025.501798","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2025.501798","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"501798"}}